Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

Novo Nordisk has launched its weight-loss drug Wegovy in India, while Eli Lilly's Mounjaro has received regulatory approval, ...

Just a couple of years ago, Kamloops mom Brandie Bugg was so overweight she couldn’t walk for more than 20 minutes and had to ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

Chinese drugmaker Innogen expects to complete a late-stage clinical trial of its experimental weight-loss drug candidate next ...

Another major insurance change coming next year will affect another large swath of Dushay’s patients: In January, BCBS ...

The former NFL player shared that now that he's lost weight, which was indeed a goal of his, there's one thing that just ...

More medicines will be spared from Medicare price negotiations, a change that is projected to wipe out billions in savings ...

Although Osbourne previously praised Ozempic in December 2022, she has since confessed that she believes she may have taken ...

Data from 32 studies concluded that the impact of exercise is modest in terms of meaningful weight loss. Caloric restriction ...

New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...

The U.S. Food and Drug Administration said on Monday it is revising the labeling of all extended-release stimulants used to ...